r esistance of 7.5% (95% confi dence interval [CI] 5.9-9.5), with respectively 1.4% (95%CI 0.7-1.6) and 27.5% (95%CI 21.8-34.1) among patients with and without a history of treatment. The MDR-TB case detection rate among retreatment cases was 68% of that estimated (129 notifi ed/170 estimated), and is >200% of that estimated among new cases (56 notifi ed/33 estimated), according to the 2007 drug resistance survey, questioning the accuracy of the 2007 estimates today.
Mongolia started implementing programmatic management of drug-resistant TB in 2006, and revised its national TB guidelines in 2009 to include the management of both drug-susceptible and -resistant TB. 4 Attempts have since been made to scale up access to MDR-TB treatment, supported by international institutions such as the Green Light Committee (providing drugs and technical assistance) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. There are several operational challenges to MDR-TB management. Diagnosis is diffi cult and is possible only in the capital city, incurring delays of several months; access to drugs and treatment is limited to centralised health facilities, and treatment is long (18-24 months) and involves many drugs. In addition, public road networks are poor and public transport is expensive; 39% of the rural population lives under the poverty line. Thus, although Mongolia is scaling up MDR-TB treatment, a number of barriers are likely to affect the time taken to initiate treatment and treatment outcomes. From the fi rst ever countrywide study in Mongolia, we report on 1) the total number of MDR-TB cases detected and their resistance patterns, 2) the proportion starting treatment and the delay between diagnosis and treatment initiation, 3) characteristics of those starting treatment, and 4) the relation between treatment outcomes and drug resistance.
METHODS

Design
This was a retrospective cohort study using routine programme data. 
Study setting and population
Diagnosis and management of MDR-TB
MDR-TB diagnosis
Sputum specimens are collected from patients presumed to have MDR-TB (Table 1) at district dispensaries in Ulaanbaatar, provincial dispensaries and sub-provincial facilities. All specimens are transported to the NTRL for culture and drug susceptibility testing (DST) against INH, RMP, ethambutol (E, EMB) and streptomycin (S, SM). Culture is performed using solid (Ogawa) medium. Species identifi cation was performed using conventional methods: morphology, p-nitrobenzoic acid and the niacin test. DST was performed using the Löwenstein-Jensen proportion method for fi rst-line drugs. Conventional culture and DST are the main diagnostic tools for patients thought to have drug-resistant TB. The GenoType ® MTBDRplus test (Hain Lifescience, Nehren, Germany) and line-probe assay are currently being used at NRTL, but were not available for this study. DST against second-line drugs is performed only for patients who do not respond well to the MDR-TB regimen.
The NRTL is the only laboratory that performs diagnostic culture and DST in the country; quality assurance is provided by its supranational laboratory and the Research Institute of Tuberculosis, Tokyo, Japan. External quality assurance results in 2011 showed high effi ciency and excellent performance. 5 After a turnaround of 4-5 months, the laboratory result is recorded in the laboratory register and relayed by the TB Department epidemiologist to the district or province dispensary TB coordinator by telephone, and, in turn, to the sub-province manager. An offi cial paper-based result follows with the culture results.
Treatment
Once MDR-TB is confi rmed, staff from the district or provincial dispensary contact the patient and enter the data into the Category 4 MDR-TB Register. MDR-TB treatment is standardised using a regimen comprising kanamycin (KM), capreomycin (CPM), ofl oxacin, levofl oxacin, ethionamide, prothionamide, cycloserine (CS), and para-aminosalicylic acid (PAS). The drugs are selected by the case management committee of the NCCD, and treatment is administered according to national guidelines ( Table 2 ). 4 Side effects are monitored clinically. In the case of KM resistance or ototoxicity, CPM is used. In the case of CS intolerance, PAS is added to the regimen. Treatment is generally initiated in the MDR-TB ward. The patient is admitted to the ward and receives treatment for at least 2 months after culture conversion, after which the patient is transferred to the district or provincial dispensary for continuation of treatment for a period of at least 18 months until completion.
Follow-up and treatment outcomes
Sputum is transported to the NTRL for follow-up smear and culture on a monthly basis during the intensive phase and every 2 months thereafter. 4 If serious drug reactions or complications are encountered, the district or province TB Coordinator presents the case to the NCCD case management committee for consensus management. Patients are given incentives such as transport allowances and free ancillary drugs. MDR-TB treatment outcomes are standardised per national guidelines, 4 which are adapted from the 2008 WHO guidelines 6 (Table 3) .
Data and analysis
For all confi rmed MDR-TB cases, socio-demographic data were collected from the laboratory register. For those enrolled for MDR-TB treatment, data were collected from MDR-TB treatment cards and the laboratory register, and included variables related to disease characteristics, time taken to enrolment on treatment, treatment outcomes and drug resistance patterns. Data were collected MDR-TB = multidrug-resistant tuberculosis; H = isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol; S = streptomycin; Km = kanamycin; Ofx = ofloxacin; Eth = ethionamide; Cs = cycloserine.
TABLE 3 Mongolia NTP definitions for MDR-TB treatment outcomes
Cured: patient in the final 12 months of treatment, culture performed every 30 days, of which the last five consecutive results are negative, or 3-4 consecutive negative cultures and no clinical symptoms Treatment completed: anti-tuberculosis treatment completed and patient is culture-negative at the end of treatment. However, less than five cultures are performed in the final 12 months of treatment or the patient has 3-4 consecutive negative cultures, but with persistent clinical symptoms or there is extra-pulmonary TB Died: patient who dies for any reason during the course of MDR-TB treatment Defaulted (lost to follow up): patient whose treatment was interrupted for ⩾2 months Failed: of the last three consecutive cultures, one or more are positive Transfer out: patient has moved to another province or district during the course of treatment NTP = National Tuberculosis Programme; MDR-TB = multidrug-resistant tuberculosis.
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into a structured proforma and then double-entered, validated and analysed using EpiData version 3.1 (EpiData Association, Odense, Denmark). Further validation was performed by crosschecking between the laboratory register, the MDR-TB register, patient cards and specifi c medical history cards available in the MDR-TB ward of the NCCD.
Ethics
Ethics approval was obtained from the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France, and the NCCD, Ulaanbaatar, Mongolia.
RESULTS
MDR-TB patients and their resistance patterns
Of 268 patients diagnosed with MDR-TB in Mongolia, 168 (63%) were resistant to HRES, 59 (22%) to HRS, 34 (13%) to HR and 7 (3%) to HRE.
Proportion initiating treatment and time from diagnosis to treatment initiation
Among the 268 MDR-TB patients, 137 (51%) were male and 52% were aged 25-34 years. A total of 139 (52%) patients were started on treatment. Reasons for non-initiation of treatment were not available at this stage, as our analysis was based on routine laboratory data and patient treatment cards. The median time from MDR-TB diagnosis to treatment initiation was 137 days (interquartile range [IQR] 43-218).
Characteristics of MDR-TB patients starting treatment
Of those who started treatment, 70/139 (50%) were male, 30.2% were aged in the 15-24 year age group, and 28.1% were in the 25-34 year age group. There were 138 cases of pulmonary TB and one of extra-pulmonary TB; 69 (50%) were secondary school and/or university students, 32 (23%) were unemployed, 24 (17%) currently employed and 14 (10%) were retired, disabled or status was unrecorded. A TB contact history was mentioned by 66 (48%) patients. There were 79 (57%) cases with WHO Category 2 failure, 37 (27%) with Category 1 failure, 11 (8%) relapses, 10 (7%) with new TB (contacts of MDR-TB) and two with 'other'. Table 4 shows the treatment outcomes by drug resistance pattern. TB treatment success (cured and treatment completed) was 69%.
Relation between treatment outcome and drug resistance patterns
There was a trend towards decreasing treatment success associated with an increasing number of drugs to which the patient was resistant, although this was not statistically signifi cant. Failure on MDR-TB treatment was 9%.
DISCUSSION
In this fi rst countrywide study of MDR-TB in Mongolia, we found that half of all patients placed on treatment were secondary and/ or university students. Nearly seven in 10 patients had a successful treatment outcome, which is encouraging. The treatment success rate of 69% in Mongolia is better than that found in a recent meta-analysis of outcome data from 9153 MDR-TB patients from 32 sites worldwide, which reported a mean success rate of only 54%. 7 However, there are a number of caveats to our study. First, only about half of all diagnosed MDR-TB patients managed to start MDR-TB treatment and there was a median delay of over 4 months between diagnosis and treatment initiation. In Mongolia, the rate of reported deaths before treatment among MDR-TB patients is about 34%. 8 Our reported outcomes thus do not include the upstream impact of delayed treatment initiation on death and loss to follow-up. In addition, those who started treatment are likely to have had a survival benefi t. Treatment outcomes are likely to be much worse if, as recently recommended by the WHO, 9 diagnosed MDR-TB patients are used as the denominator for assessing programme performance.
The strengths of this study are that we used countrywide data and our fi ndings are thus representative of the situation in Mongolia. Data were carefully validated using patient cards and registers, and are thus robust. We adhered to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 10 guidelines, including ethics considerations. 11 One important limitation is that we do not have information on what happened to patients who were diagnosed with MDR-TB but were not enrolled on treatment. From a public health perspective, such patients are at high risk of death and transmission of resistant TB. Of additional concern is the 9% failure rate, which may be an early warning of pre-XDR (extensively drug-resistant) or XDR-TB. Further research on these two issues is needed.
The 2009 World Health Assembly resolved that at least 75% of all notifi ed MDR-TB cases should have a successful treatment outcome by 2015. 12 Like many other countries, Mongolia thus needs to accelerate progress toward early diagnosis and access to treatment. Ways forward include moving to more rapid MDR-TB diagnostic technology. This is already being done with the introduction of culture on liquid medium in 2011. The Mongolian NTRL now has the capacity to perform smear, culture, species identifi cation and fi rst-line DST using solid media. However, the NTRL can perform only conventional solid culture, bio-chemical identification and solid DST. The possibility of using Xpert ® MTB/RIF technology (Cepheid, Sunnyvale, CA, USA) also needs to be explored, as this allows diagnosis to be decentralised. The delays in diagnosis and treatment initiation highlight an urgent need for uptake of molecular techniques for MDR-TB testing. Measures to (10) 12 (9) 11 (8) 1 (1) 9 (7) 6 (4) 3 (2) decentralise MDR-TB treatment to a larger number of facilities are also urgently needed, and this is now underway in eight provinces. Community awareness and involvement also needs to be enhanced and this issue has been taken on board.
A specifi c problem is the high proportion of students with MDR-TB. Although this maybe an indication of community transmission, or relatively better access, schools can be a hot spot for TB transmission. The very cold climate, closed windows and congested dormitories in residential schools may be partially responsible. Urgent measures are needed to investigate this issue further.
In conclusion, the fi rst countrywide audit of MDR-TB management in Mongolia is encouraging but highlights a number of a reas that need specifi c attention, including the need to ensure earlier access to treatment.
Contexte : Dix-huit unités de traitement de la tuberculose multirési -stante (TB-MR) en Mongolie. Objectif : Déterminer le nombre total de cas de TB-MR détectés et leur profil de résistance, la proportion et les caractéristiques des cas en début de traitement, le délai entre le diagnostic et la mise en route du traitement, ainsi que la relation entre le résultat du traitement et la résistance aux médicaments. Schéma : Etude de cohorte rétrospective basée sur les données de routine du programme. Résultats : Les cas résistants étaient au nombre de 168 (63%) pour l'association HRES, 59 (22%) pour HRS, 34 (13%) pour HR et 7 (3%) pour HRE. Sur les 268 patients porteurs d'une TB-MR, 139 (52%) ont débuté leur traitement. 69 (50%) étaient des lycéens ou des étudiants, 35 (25%) étaient sans emploi, 24 (17%) avaient un travail et 14 (8%) étaient retraités, invalides ou non enregistrés. La durée médiane entre le diagnostic et la mise en oeuvre du traitement était de 137 jours (IQR 43-218). Le taux de réussite du traitement était de 69% ; les 9% d'échec pourraient correspondre à une tuberculose ultrarésistante (TB-XDR) ou pré-XDR. Conclusion : Près de sept patients atteints de TB-MR sur 10 en Mongolie ont été traités avec succès, ce qui est encourageant. Les problèmes particuliers constatés sont la proportion élevée d'étudiants, le fait que seulement la moitié des patients diagnostiqués aient eu accès au traitement et le délai inacceptable de 4 mois entre le diagnostic et le traitement. Ces problèmes doivent être résolus.
Marco de referencia:
Dieciocho unidades de tratamiento de la tuberculosis multidrogorresistente (TB-MDR) en Mongolia. Objetivo: Determinar el número total de casos de TB-MDR detectados y el perfil de resistencia, la proporción de casos que iniciaron trata miento y sus características, el retraso entre el diagnóstico y el comienzo del tratamiento y la relación entre los desenlaces terapéuti-cos y la resistencia a los medicamentos. Método: Fue este un estudio de cohortes retrospectivo a partir de los datos corrientes del programa. Resultados: Se observaron 168 casos de resistencia a HRES (63%), 59 casos resistentes a HRE (22%), 34 casos de resistencia a HR (13%) y 7 casos resistentes a HRE (3%). De los 268 pacientes con diagnó-stico de TB-MDR, 139 comenzaron el tratamiento (52%). Sesenta y nueve pacientes eran estudiantes de secundaria o universitarios (50%), 35 pacientes estaban desempleados (25%), 24 tenían un empleo (17%) y 14 pacientes eran jubilados, minusválidos o no contaban con definición en los registros (8%). La mediana del lapso entre el establecimiento del diagnóstico de TB-MDR y el comienzo del tratamiento fue 137 días (IQR 43-218). La tasa de éxito terapéutico fue 69% y se observó 9% de casos con fracaso terapéutico, que pueden corresponder a casos de tuberculosis extremadamente drogorresistente (TB-XDR) o a una alarma temprana de casos pre-XDR. Conclusión: Cerca de siete de cada 10 pacientes en Mongolia alcanzaron un desenlace terapéutico favorable, lo cual augura buenas perspectivas. Los problemas específicos observados fueron una alta proporción de estudiantes, solo cerca de la mitad de los pacientes con diagnóstico establecido accedieron al tratamiento y se observó un retraso inaceptable del tratamiento de 4 meses. Es importante aportar respuestas a estas dificultades.
